ID   BID019
AC   CVCL_E6DY
SY   Beth Israel Deaconess 019
RX   PubMed=31467113;
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Asn771_His772insHis; Zygosity=Unspecified (PubMed=31467113).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223;
RA   Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M.,
RA   Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A.,
RA   Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B.,
RA   Kobayashi S.S.;
RT   "TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase
RT   inhibitor with a broad spectrum of preclinical activity against
RT   clinically relevant EGFR mutations.";
RL   Mol. Cancer Res. 17:2233-2243(2019).
//